Incyte Corporation
Incyte and Novartis Settle Royalty Dispute for JAKAFI
Summary
On May 11, 2025, Incyte Corporation and Novartis Pharma AG entered into a settlement agreement regarding a royalty dispute over JAKAFI sales. Incyte agreed to pay Novartis $280.0 million to settle the dispute and reduce the royalty rate on future sales by 50%. The remaining balance of the accrued royalties will be recorded in Incyte's financials for Q2 2025.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement